research papers
Influence of heme and pH on the oligomeric states of Brucella melitensis bacterioferritin
aDepartment of Chemistry, Laboratoire de Chimie Biologique Structurale (CBS), University of Namur (UNamur), Namur Research Institute for Life Sciences (NARILIS), Namur Institute of Structural Matter (NISM), 61 Rue de Bruxelles, 5000 Namur, Belgium
*Correspondence e-mail: [email protected], [email protected]
Bacterioferritin from Brucella melitensis (BmBfr) is a protein that plays essential roles in oxidative stress management and metal homeostasis in the bacterium. It presents itself as a 24-mer forming a spherical nanocage, allowing further applications such as drug delivery and nanoparticle synthesis. Studying the oligomerization process is thus important for a deeper understanding of the protein. In this work, two forms of the protein were studied: with the heme cofactor (holo BmBfr) and without the cofactor (apo BmBfr). Analyses were performed using size-exclusion chromatography, thermal shift analysis and structure determination of apo BmBfr by X-ray crystallography. This revealed that oligomerization is not possible with the apo form, since the heme is essential for dimer formation, which is the first oligomerization step. Further oligomerization can occur at a pH above 5.0, where interface interactions are favorable, to form a highly stable 24-mer state. Those findings allowed us to suggest an oligomerization mechanism for BmBfr.
Keywords: bacterioferritin; Brucella melitensis; oligomerization; interfaces; crystallization; thermal stability.
PDB reference: apo bacterioferritin from Brucella melitentsis, 9gzu
1. Introduction
Brucella species are facultative intracellular pathogens responsible for brucellosis, a zoonosis targeting mammals, and are thus of major public health and economic importance in many developing regions (Laine et al., 2023
; Lokamar et al., 2020
; Kiiza et al., 2023
). Brucella are α-proteobacteria which infect diverse cell types, including phagocytes, where they replicate while avoiding host immune defenses (Ackermann et al., 1988
; Corbel et al., 2006
; Moreno, 2014
). To achieve this, they have evolved mechanisms that disrupt dendritic cell functions, thereby avoiding detection by the host immune system (Lacerda et al., 2013
; Salcedo et al., 2008
). The different species of Brucella that exist differ in their membrane structure and secretion systems, which may contribute to their distinct host preferences (Eschenbrenner et al., 2006
; Velasco et al., 2000
).
Survival within macrophages requires Brucella to withstand profound iron limitation and high levels of oxidative stress. Under these intracellular conditions, efficient management of iron becomes essential to maintain metabolic activity while preventing the iron-driven formation of reactive oxygen species (Baldwin & Roop, 2002
).
Ferritin-like proteins such as bacterioferritin (Bfr; Fig. 1
) are therefore central to Brucella pathophysiology, playing essential roles in oxidative stress management and metal homeostasis in bacteria. Bacterioferritins (Bfrs) belong to the ferritin superfamily and serve as key iron-storage and detoxification systems in many bacteria (Almirón & Ugalde, 2010
; Arosio et al., 2009
; Crow et al., 2009
). They assemble into a highly conserved homo-24-mer protein nanocage with a large internal cavity that mineralizes Fe3+, thereby preventing the accumulation of redox-active Fe2+. Each subunit adopts a characteristic four-helix-bundle fold containing a di-iron ferroxidase center. Mechanistic studies in Escherichia coli have defined the canonical ferroxidation pathway: two Fe2+ ions bind the catalytic site, react with O2 or H2O2 to generate a di-Fe3+ intermediate and undergo turnover supported by a tyrosine-based electron-transfer network (Bradley et al., 2014
, 2015
, 2024
). Other mechanistic studies in Pseudomonas aeruginosa showed that a second protein, the bacterioferritin-associated (Bfd), is involved in the transport of iron ions to the ferroxidase center, forming a Bfr–Bfd complex structure (Weeratunga et al., 2010
; Yao et al., 2012
). This model can be extrapolated to B. melitensis bacterioferritin (BmBfr), which possesses a highly conserved structure (Liu et al., 2026
).
Despite only 48.4% sequence identity between BmBfr and E. coli Bfr, and 21.1% identity between BmBfr and human ferritin, ferritin-like proteins consistently retain the 24-mer assembly and overall structural design (Andrews et al., 1989
; Costanzo et al., 1984
; Denoel et al., 1995
; van Eerde et al., 2006
; Wang et al., 2006
). Understanding the oligomeric state of bacterioferritins is thus crucial for interpreting how they control iron flux. Previous studies in other organisms suggest that the ferritin-assembly process occurs spontaneously, with the dimer as the first stable intermediate (Ebrahimi et al., 2015
). It subsequently oligomerizes into a final 24-meric cage. Bacterioferritin differs from other ferritins in that it contains up to 12 heme groups per 24-mer (Andrews et al., 1995
; Crow et al., 2009
). These heme groups are bound at the dimeric interface, deep below the protein surface, and coordinate to a methionine residue in each monomer (Mohanty et al., 2021
; Rivera, 2017
; Wang et al., 2015
; Wong et al., 2009
). Studies on E. coli, Mycobacterium tuberculosis and P. aeruginosa indicate that the heme group is mainly involved in structural stability and facilitates and iron release from the bacterioferritin core (Le Vay et al., 2020
; Mohanty et al., 2021
; Pullin et al., 2021
; Wang et al., 2015
) but is not essential for the oligomerization process (Andrews et al., 1995
; Mohanty et al., 2021
; Parida et al., 2025
).
Oligomerization is often modulated by physicochemical conditions, including pH, ionic strength, temperature and ligand binding (Ali & Imperiali, 2005
; Gaber & Pavšič, 2021
; Liu & Eisenberg, 2002
). These transitions can directly affect ferritin-pore dynamics, ferroxidase cooperativity and metal-trafficking pathways.
The capacity of ferritin nanocages to assemble, disassemble and be engineered has inspired applications ranging from targeted drug delivery and imaging to confined nanoparticle synthesis and protein encapsulation (Johnson-Arbor & Dubey, 2023
; Mohanty et al., 2022
; Saldan et al., 2015
; Song et al., 2021
; van der Ven et al., 2023
; Wang et al., 2011
; Zheng et al., 2009
; Zhen et al., 2013
).
Here, we report structural characterization of BmBfr combining size-exclusion chromatography (SEC) and X-ray crystallography (XRD). SEC is used to define its oligomeric state and solution behavior at different pH values, while XRD was performed on apo BmBfr to provide a high-resolution description of its quaternary assembly and ferroxidase center and compare it with the holo BmBfr structure (PDB entry 3fvb; Seattle Structural Genomics Center for Infectious Disease. unpublished work). Particular attention is given to the effect of the heme cofactor in BmBfr assembly. While heme is not considered to be essential for oligomerization in other bacterioferritins, our observations suggest that its contribution in B. melitensis may differ. We therefore investigate the structural and oligomeric consequences of heme binding by comparing apo and holo BmBfr.
2. Materials and methods
2.1. Enzyme overexpression and purification
B. melitensis bacterioferitin was overexpressed after induction with isopropyl β-D-1-thiogalactopyranoside (IPTG) in E. coli cells (BL21pLysS strain) containing a plasmid coding for the His-tagged protein (BrabA.00028.a) provided by the Seattle Structural Genomics Center for Infectious Disease (https://www.ssgcid.org), which is supported by Federal Contract No. 75N93022C00036 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services. Bacteria were grown in liquid lysogeny broth medium (LB) at 37°C until an optical density of 0.6 at 600 nm was reached, after which induction was performed for 3 h by adding 1.0 mM IPTG in the absence of hemin. The cells were then lysed by sonication and centrifuged. The supernatant was recovered and purified by immobilized metal-affinity (IMAC). The His-tag used to facilitate the purification by IMAC was cleaved using HRV3C protease and proteins were recovered in 50 mM Tris buffer pH 8 supplemented with 150 mM NaCl. Yields were usually good, with 40–50 mg protein being produced per litre of bacterial culture.
2.2. Heme incorporation
BmBfr was produced as an apoprotein. To incorporate its heme cofactor, the following method was used (inspired by Wang et al., 2015
): 2.5 ml BmBfr concentrated to 0.8 mg ml−1 was heated for 15 min at 60°C in the presence of hemin chloride. If needed, excess hemin was then removed by decreasing the pH to 3.5 and filtration at 0.2 µm. Heme incorporation was checked by UV–visible spectrometry.
2.3. Crystallization, data collection and processing
Batches of BmBfr produced in the absence of hemin (apo BmBfr) yielded useful crystals at pH 7.5 (0.1 M HEPES buffer) using 1.5 M lithium sulfate as a precipitating agent. For crystallization, the protein was concentrated to 10 mg ml−1 and the hanging-drop method was used with 0.5 µl enzyme solution mixed with 0.5 µl well solution (SG2 crystallization kit from Molecular Dimensions; Abrahams & Newman, 2021
; Fazio et al., 2014
). Crystals took three days to grow in octahedral forms measuring about 100 µm.
Apo BmBfr crystals were cryoprotected with 20% glycerol and diffraction data were collected to a resolution of 1.97 Å on beamline PROXIMA-2A (100 K, wavelength of 0.97857 Å and EIGER X 9M detector) at Synchrotron SOLEIL, Gif-sur-Yvette, Paris (Duran et al., 2013)
, using MxCuBE (Oscarsson et al., 2019
) for data collection and XDS/XSCALE (Kabsch, 2010
) for processing. Molecular replacement was performed by Phaser (McCoy et al., 2007
) in Phenix (Liebschner et al., 2019
) using PDB entry 3fvb. Phenix, Coot (Emsley et al., 2010
) and eLBOW (Moriarty et al., 2009
) were used to build the model and refine the structure. The final coordinates were deposited as PDB entry 9gzu. Figures were generated using PyMOL (DeLano, 2002
).
Data-collection and refinement statistics are given in Table 1
for the apo BmBfr structure.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2.4. In silico study of oligomeric state via PISA
Study of the protein interfaces, surfaces and stability of the assemblies was performed using the PDBePISA web interface (Krissinel & Henrick, 2007
). Atomic coordinates of both the holo and apo BmBfr crystal structures were analyzed.
2.5. Experimental study of the oligomerization state by size-exclusion chromatography (SEC)
measurements were performed on an NGC Bio-Rad FPLC using a Cytiva Superdex 200 Increase 10/300 GL column. After column equilibration with an appropriate buffer, a 300 µl sample of protein at 6 mg ml−1 was loaded and eluted at 0.5 ml min−1. A calibration curve was performed in working buffer with Gel Filtration Markers Kit for Protein Molecular Weights 29 000–700 000 Da from Sigma–Aldrich, showing a good correlation between molecular weight (Mw) and the ratio between elution volume and dead volume (Ve/Vo),
Good correlation was also obtained with the hydrodynamic radius (Rh) determined by the Hullrad program (Fleming & Fleming, 2018
),
Stock solutions of BmBfr in the presence or absence of hemin at different pH values (50 mM sodium citrate or Tris, 0.150 M NaCl, pH 3.5–7.5) were analyzed to deduce their oligomeric states in solution. To determine the oligomeric states, the hydrodynamic radii were calculated using the calibration equation and compared with those predicted by the Hullrad program (Supplementary Table S1).
2.6. Protein stability studied by thermal shift assay
Thermal shift assays (TSAs) were performed using the StepOnePlus Real-Time PCR system from ThermoFisher Scientific. The wells of the PCR plate were filled with 20 µl of a solution containing 12 µg protein and the desired amount of the tested molecule, in the presence of SYPRO Orange from ThermoFisher Scientific (1× concentrated). Measurements of fluorescence at 623 nm (excitation at 570 nm) were performed every degree between 25 and 98°C. TSA curves were analyzed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, California, USA) by fitting a Boltzmann sigmoid to the fluorescence transition.
3. Results
3.1. Crystal structure of BmBfr in the presence and absence of heme cofactor
The of apo BmBfr determined in this work was compared with that of holo BmBfr (PDB entry 3fvb; Seattle Structural Genomics Center for Infectious Disease. unpublished work). B. melitensis bacterioferritin crystallizes, both in the apo and holo forms, as a 24-subunit protein that self-assembles into a spherical nanocage, adopting the classical ferritin fold observed in similar proteins (Arosio et al., 2009
; Dautant et al., 1998
; Frolow et al., 1994
; Granier et al., 2001
; Jobichen et al., 2023
; Lawson et al., 1991
; Précigoux et al., 1994
; Yao et al., 2012
). Each subunit has a four-helix bundle fold, and the 24 subunits assemble to create a 12 nm outer diameter shell with an 8 nm interior cavity (Fig. 2
a).
| Figure 2 Crystal structures of B. melitensis bacterioferritin. (a) 24-subunit assembly creating a 12 nm outer diameter shell with an 8 nm interior cavity. (b) Comparison of the dimer accommodating the heme cofactor (green) in the holo BmBfr structure (left, white) or without cofactor (apo BmBfr, blue, right). An alignment of this interface in both structures is presented (middle). (c) Comparison of the ferroxidase centers in the holo BmBfr (left) or apo BmBfr structures (right). (d) Picture of apo BmBfr crystals. |
In the presence of added hemin, holo BmBfr contains 12 heme cofactors bound at the interfaces between subunits related by twofold symmetry. In the absence of hemin, apo BmBfr adopts the same 24-mer oligomeric state but the heme cofactor is absent at the dimeric interfaces, as confirmed by careful analysis of electron density at this interface (polder maps; Supplementary Fig. S1). These differences do not induce major conformational changes between the structures, as underlined by an overall r.m.s.d. measured on all Cα atoms of 0.24 Å (Fig. 2
b).
Another major difference is the presence of iron in the holo BmBfr crystal structure that is not present in the apo BmBfr structure (Fig. 2
c).
Crystals of apo BmBfr analyzed by XRD showed a slight brown-red coloration (Fig. 2
d) that could indicate the presence of heme in the protein structure (Eaton & Hochstrasser, 1968
; Pfanzagl et al., 2020
; Rodrigues et al., 2006
). Nucleation points may have been formed through the crystallization of the holo form. The presence of holo BmBfr in apo solution observed by SEC strengthens this idea.
3.2. In silico analysis of the oligomeric states of BmBfr
PISA (Protein Interfaces, Surfaces, and Assemblies; Krissinel & Henrick, 2007
) is a powerful and widely used tool for predicting protein oligomeric states from crystal structures. The program analyzes protein crystal structures to identify the most probable oligomeric state by assessing macromolecular interactions. It does this by calculating the Gibbs free energy of dissociation (ΔG°) for various potential assemblies and using this energy to predict which assemblies are stable in solution.
Three primary interfaces were found with PISA, as shown in Fig. 3
. Table 2
provides characteristics of selected interfaces within the 24-mer oligomeric structures of apo and holo BmBfr.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Figure 3 Primary interfaces of (a) apo and (b) holo BmBfr selected with PISA: interface 1 (dimeric interface) is in blue, interface 2 is in red and interface 3 is in green. |
In both structures, the dimeric interface (interface 1) is the most stable interface identified by PISA. The stability of this interface is associated with a series of interactions, including salt bridges between Arg30 and Asp60 and between Arg30 and Asp56. When occupied by the heme cofactor in holo BmBfr, additional interactions appear at the dimeric interface, including the coordination of the heme iron cation by Met52 and an additional salt bridge involving the carboxylate of the heme and Arg45 (Fig. 4
). The stability of this interface is also associated with a negative solvation ΔG° (Table 2
), which is more favorable in the presence of the heme cofactor.
| Figure 4 Selected interactions at the dimeric interface of holo (top) and apo (bottom) BmBfr. |
Interfaces 2 and 3 display the same interactions and a similar solvation ΔG° for both apo and holo BmBfr, suggesting that the effect of heme is negligible for these interfaces. This observation is consistent with expectation, as the heme is distant from these interfaces (more than 16 Å).
3.3. Determination of oligomeric states in solution by size-exclusion chromatography
The oligomeric state of the protein can be affected by its environment. Crystallization occurs at a high protein concentration and with crystallization agents, leading to different oligomeric behavior to that in solution. Oligomeric interfaces predicted by PISA are then biased by the intrinsic crystal condition on which the analysis is based. Therefore, oligomeric states of BmBfr in solution were analyzed by size-exclusion chromatography to elucidate the effect of the aforementioned bias.
In the absence of added heme in the solution, apo BmBfr eluted as a major peak corresponding to a monomer (Fig. 5
a). The Rh measured by SEC (2.6 nm at pH 5 and 2.7 nm at pH 7.5) is indeed close to that predicted with Hullrad (2.4 nm; Supplementary Table S1). A neglectable portion of apo BmBfr eluted as a 24-mer. In the presence of added heme, the oligomeric state of holo BmBfr depended on the pH of the solution (Fig. 5
b). Indeed, holo BmBfr eluted as a mixture of monomer (26%), dimer (7%) and 24-mer (67%) at pH 7.5. At pH 5.0, holo BmBfr exists as a mixture of monomer (74%) and 24-mer (26%). At lower pH (3.5) no traces of the 24-mer are observed, with holo BmBfr being essentially in the form of a dimer (92%) and traces of monomer (8%). The acidity of the solution thus has an important effect on the oligomeric state of the protein (Table 3
).
| ||||||||||||||||||||||
| | Figure 5 SEC analysis of apo BmBfr (a) and holo BmBfr (b) at different pH values. pH values of 3.5 and 5.0 were obtained with 50 mM citrate buffer and pH 7.5 with 50 mM Tris buffer. All buffers contain 250 mM NaCl. |
Heme incorporation of the samples was checked by UV–visible absorbance to evaluate the Soret peak (Supplementary Fig. S3), confirming that the monomer is indeed heme-free while the dimer and 24-mer incorporate the cofactor.
3.4. Stability analysis of BmBfr by thermal shift analysis (TSA)
BmBfr monomer stability was assessed over a wide range of pH values using the apoprotein (Fig. 6
a). Two buffers were used to fix the pH (citrate and phosphate), showing a small effect of the buffer nature on protein stability. In both cases, maximum stability is achieved around pH 4.7. It corresponds to the protein isoelectric point, which was calculated to be 4.7 using ProtParam (Gasteiger et al., 2005
).
| | Figure 6 (a) Melting temperature of apo BmBfr at different pH values. Two buffers were used to fix the pH: phosphate (black) and citrate (red). (b) Thermal shift assay measurements for holo BmBfr in 50 mM citrate pH 3.5 [red, Tm(1) = 49.6 ± 0.1°C, Tm(2) = 70.5 ± 0.1°C] and apo BmBfr in 50 mM phosphate pH 7.5 (black, Tm = 38.0 ± 0.3°C). |
Thermal shift analysis was also performed to determine the stability of the 24-mer, but its exact melting temperature could not be assessed because of its great stability (Tm > 90°C at pH values between 4.0 and 8.0). This result is consistent with available information in the literature (Qu et al., 2021
). It was however possible to compare the dimer stability with that of the monomer at pH 3.5, where they are the only two states present in solution (Fig. 6
b). The TSA curve of the dimer–monomer mixture at pH 3.5 (red) is compared with that for the monomer of the apoprotein at pH 7.5. Only one transition is observed in the monomer curve, while two are visible in the monomer–dimer curve, confirming the presence of two oligomeric states in solution. Based on the monomer curve and Fig. 6
(a), the first transition can be ascribed to the monomer, showing stabilization of the dimer in solution (around 21°C more stable than the monomer).
4. Discussion
In this work, two crystal structures of BmBfr were studied, one obtained using the holo form (heme-containing form) and the other obtained using the apo form. The two structures are almost identical apart from the presence of heme at the dimeric interface in holo BmBfr and the composition of the ferroxidase center (Figs. 2
b and 2
c). Both forms crystallize in a face-centered cubic lattice, with similar unit-cell parameters but with different symmetry elements: holo BmBfr (PDB entry 3fvb) was crystallized in a less symmetric space group than apo BmBfr (PDB entry 9gzu).
To develop a deeper understanding of the distinctions between the structures, interfaces were studied with the PISA tool, highlighting three main interfaces in the 24-meric assemblies (Fig. 3
). The first interface is the dimeric interface formed between two subunits related by twofold symmetry. This interface creates the heme-bonding pocket where the cofactor is present for the holo form only (Fig. 4
). It is the most stable interface, and is even more stable in the presence of heme (Table 2
), as previously observed for bacterioferritins from E. coli and M. tuberculosis (Le Vay et al., 2020
; Mohanty et al., 2021
).
This interface is the source of the main difference between apo and holo BmBfr. Specifically, in the absence of heme (apo BmBfr) this interface is not strong enough to allow dimerization in solution, as suggested by the SEC results, where only the monomer is observed at different pH values (Fig. 5
a). However, after incubation with heme cofactor, the protein (holo BmBfr) oligomerizes to form a dimer, which was shown to be more stable than the monomer by TSA analysis at pH 3.5 (Fig. 6
b). Depending on the pH conditions, dimers can oligomerize as a 24-mer, as revealed by the SEC results (Fig. 5
b). These results suggest that dimer formation is essential for further oligomerization into 24-mers and that heme incorporation is essential for dimerization. This behavior is unexpected and contrasts with that of bacterioferritins from E. coli, M. tuberculosis and P. aeruginosa, which show stable dimeric or 24-meric species even in the absence of heme cofactor (Andrews et al., 1995
; Mohanty et al., 2021
; Stein et al., 2026
). The requirement for heme in dimer assembly may constitute the evolutionary divergence between classical bacterioferritins and heme-deficient ferritin-like proteins. The heme group in BmBfr thus has three functions: facilitating electron transfer and iron release from the core, increasing structural stability and enabling oligomerization.
To further oligomerize into a 24-mer, two complementary interfaces are created between two different dimers (interfaces 2 and 3 in Fig. 3
). These interfaces are completely conserved in the apo and holo BmBfr crystal structures. The formation of the 24-mer holo BmBfr leads to a very stable oligomeric state, with a transition above 90°C as observed by TSA. This high thermal stability of ferritins has previously been documented in the literature (Qu et al., 2021
).
The interfaces obtained for apo BmBfr are probably biased by the intrinsic crystallization conditions, as they are only observed in the solid crystalline state. Indeed, no oligomeric states higher than a monomer were observed in solution using SEC (Fig. 5
a). The apo BmBfr crystal could then be obtained because of the high protein concentration and/or after the nucleation of holo BmBfr traces in the sample initiating crystallization, as suggested by the slightly brown-red crystal coloration (Fig. 2
d).
Analyses were performed using SEC to further characterize holo BmBfr oligomerization in solution (Fig. 5
b). Previous work in the literature for bacterioferritins from other species has shown variation in oligomeric states when going from highly acidic to neutral pH (Bradley et al., 2022
; Mohanty et al., 2021
). Considering this information, SEC measurements were performed at three different pH values (3.5, 5.0 and 7.5), showing three different oligomeric forms: monomer, dimer and 24-mer. Only the dimer and monomer are observed at pH 3.5, highlighting that this condition prevents 24-mer formation, probably by the destabilization of interfaces 2 and 3 at low pH. This destabilization is linked to the protonation of acidic residues involved in saline bridges and hydrogen bonding such as Asp34, Glu106, Glu128 and Glu174. At pH 5.0 only the 24-mer and monomer are observed, suggesting that the dimer–24-mer equilibrium is probably shifted to the 24-mer state. This is not surprising since the pH is close to the isoelectric point, promoting protein–protein interactions (Zhang et al., 2011
). Finaly, all states are visible at pH 7.5, at which the 24-mer can be formed but with weaker protein–protein interactions (at interfaces 2 and 3), thus coexisting with the dimer. The presence of the monomer at pH 5.0 and 7.5 is probably due to incomplete heme incorporation of the sample.
Altogether, the different results obtained by crystallography, interface analysis, SEC and TSA lead to the suggestion of a complex oligomerization mechanism ruled by heme incorporation and pH regulation (Fig. 7
).
| | Figure 7 Oligomerization mechanism of BmBfr. The first step is ruled by heme incorporation to form the dimer, stabilized by highly favorable interactions in interface 1 (blue). Dimers then assemble into a higher oligomeric state using complementary interactions in interfaces 2 and 3 (red and green), above pH 5, to form the 24-mer. |
Additional computational analyses could validate the actual mechanism of oligomeric disruption with greater confidence. They could include energy analysis to analyze hydrogen bonds (short range/long range/backbone/side chain), van der Waals interactions and electrostatic interactions to obtain clarity on the mechanism of stabilization. Constant pH replica exchange (CpHMD; Mongan et al., 2004
; Swails et al., 2014
) could also be carried out for both apo and holo forms of BmBfr. Unlike standard MD, which uses fixed protonation states, CpHMD allows titratable residues (e.g. His, Asp snd Glu) to change protonation states during the simulation based on the surrounding environment and the target pH, enabling the study of pH-dependent structural changes and binding. This would further help to understand the transition in hydrogen-bond and other chemical interactions during oligomer disruption and complement the experimental evidence provided in the present work.
Supporting information
PDB reference: apo bacterioferritin from Brucella melitentsis, 9gzu
Supplementary Figures and Table. DOI: https://doi.org/10.1107/S2059798326006625/jb5073sup1.pdf
Acknowledgements
The authors would like to thank the URBM (UNamur) laboratory for facilities access to produce BmBfr protein, in particular Xavier De Bolle for fruitful discussions, Synchrotron SOLEIL for their precious help with the XRD experiments and SSGCID for kindly sending the plasmid used for protein production.
Funding information
This work was supported by the French Community of Belgium (ARC 21/26-115). Computational resources were provided by the Consortium des Équipements de Calcul Intensif (CÉCI), funded by the Fonds de la Recherche Scientifique de Belgique (FRS–FNRS) under Grant No. 2.5020.11 and by the Walloon Region.
References
Abrahams, G. & Newman, J. (2021). Acta Cryst. D77, 1437–1450. Web of Science CrossRef IUCr Journals Google Scholar
Ackermann, M. R., Cheville, N. F. & Deyoe, B. L. (1988). Vet. Pathol. 25, 28–35. CrossRef CAS PubMed Google Scholar
Ali, M. H. & Imperiali, B. (2005). Bioorg. Med. Chem. 13, 5013–5020. Web of Science CrossRef PubMed CAS Google Scholar
Almirón, M. A. & Ugalde, R. A. (2010). J. Microbiol. 48, 668–673. PubMed Google Scholar
Andrews, S. C., Brun, N. E. L., Barynin, V., Thomson, A. J., Moore, G. R., Guest, J. R. & Harrison, P. M. (1995). J. Biol. Chem. 270, 23268–23274. CrossRef CAS PubMed Google Scholar
Andrews, S. C., Harrison, P. M. & Guest, J. R. (1989). J. Bacteriol. 171, 3940–3947. CrossRef CAS PubMed Google Scholar
Arosio, P., Ingrassia, R. & Cavadini, P. (2009). Biochim. Biophys. Acta, 1790, 589–599. Web of Science CrossRef PubMed CAS Google Scholar
Baldwin, C. L. & Roop, R. M. (2002). Opportunistic Intracellular Bacteria and Immunity, edited by L. J. Paradise, H. Friedman & M. Bendinelli, pp. 255–279. Boston: Springer. Google Scholar
Bradley, J. M., Bugg, Z., Sackey, A., Andrews, S. C., Wilson, M. T., Svistunenko, D. A., Moore, G. R. & Le Brun, N. E. (2024). Angew. Chem. Int. Ed. 63, e202401379. CrossRef Google Scholar
Bradley, J. M., Gray, E., Richardson, J., Moore, G. R. & Le Brun, N. E. (2022). Nanoscale, 14, 12322–12331. CrossRef CAS PubMed Google Scholar
Bradley, J. M., Moore, G. R. & Le Brun, N. E. (2014). J. Biol. Inorg. Chem. 19, 775–785. Web of Science CrossRef CAS PubMed Google Scholar
Bradley, J. M., Svistunenko, D. A., Lawson, T. L., Hemmings, A. M., Moore, G. R. & Le Brun, N. E. (2015). Angew. Chem. Int. Ed. 54, 14763–14767. CrossRef CAS Google Scholar
Corbel, M. J., Food and Agriculture Organization of the United Nations, World Health Organization & World Organisation for Animal Health (2006). Brucellosis in Humans and Animals. Geneva: World Health Organization Google Scholar
Costanzo, F., Santoro, C., Colantuoni, V., Bensi, G., Raugei, G., Romano, V. & Cortese, R. (1984). EMBO J. 3, 23–27. CrossRef CAS PubMed Google Scholar
Crow, A., Lawson, T. L., Lewin, A., Moore, G. R. & Brun, N. E. L. (2009). J. Am. Chem. Soc. 131, 6808–6813. Web of Science CrossRef PubMed CAS Google Scholar
Dautant, A., Meyer, J.-B., Yariv, J., Précigoux, G., Sweet, R. M., Kalb (Gilboa), A. J. & Frolow, F. (1998). Acta Cryst. D54, 16–24. Google Scholar
DeLano, W. L. (2002). PyMOL. http://www.pymol.org. Google Scholar
Denoel, P. A., Zygmunt, M. S., Weynants, V., Tibor, A., Lichtfouse, B., Briffeuil, P., Limet, J. N. & Letesson, J.-J. (1995). FEBS Lett. 361, 238–242. CrossRef CAS PubMed Google Scholar
Duran, D., Couster, S. L., Desjardins, K., Delmotte, A., Fox, G., Meijers, R., Moreno, T., Savko, M. & Shepard, W. (2013). J. Phys. Conf. Ser. 425, 012005. CrossRef Google Scholar
Eaton, W. A. & Hochstrasser, R. M. (1968). J. Chem. Phys. 49, 985–995. CrossRef CAS PubMed Web of Science Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Eschenbrenner, M., Horn, T. A., Wagner, M. A., Mujer, C. V., Miller-Scandle, T. L. & DelVecchio, V. G. (2006). J. Proteome Res. 5, 1731–1740. CrossRef PubMed CAS Google Scholar
Fazio, V. J., Peat, T. S. & Newman, J. (2014). Acta Cryst. F70, 1303–1311. Web of Science CrossRef IUCr Journals Google Scholar
Fleming, P. J. & Fleming, K. G. (2018). Biophys. J. 114, 856–869. Web of Science CrossRef CAS PubMed Google Scholar
Frolow, F., Kalb, A. J. & Yariv, J. (1994). Nat. Struct. Mol. Biol. 1, 453–460. CrossRef CAS Google Scholar
Gaber, A. & Pavšič, M. (2021). Int. J. Mol. Sci. 22, 9081. Web of Science CrossRef PubMed Google Scholar
Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D. & Bairoch, A. (2005). The Proteomics Protocols Handbook, edited by J. M. Walker, pp. 571–607. Totowa: Humana Press. Google Scholar
Granier, T., Gallois, B., Langlois d'Estaintot, B., Dautant, A., Chevalier, J.-M., Mellado, J.-M., Beaumont, C., Santambrogio, P., Arosio, P. & Precigoux, G. (2001). Acta Cryst. D57, 1491–1497. CrossRef CAS IUCr Journals Google Scholar
Honarmand Ebrahimi, K., Hagedoorn, P.-L. & Hagen, W. R. (2015). Chem. Rev. 115, 295–326. Web of Science CrossRef CAS PubMed Google Scholar
Jobichen, C., Ying Chong, T., Rattinam, R., Basak, S., Srinivasan, M., Choong, Y. K., Pandey, K. P., Ngoc, T. B., Shi, J., Angayarkanni, J. & Sivaraman, J. (2023). PNAS Nexus, 2, pgad235. Google Scholar
Johnson-Arbor, K. & Dubey, R. (2023). Doxorubicin. Treasure Island: StatPearls Publishing. Google Scholar
Kabsch, W. (2010). Acta Cryst. D66, 125–132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Kiiza, D., Denagamage, T., Serra, R., Maunsell, F., Kiker, G., Benavides, B. & Hernandez, J. A. (2023). Prev. Vet. Med. 213, 105878. CrossRef PubMed Google Scholar
Krissinel, E. & Henrick, K. (2007). J. Mol. Biol. 372, 774–797. Web of Science CrossRef PubMed CAS Google Scholar
Lacerda, T. L. S., Salcedo, S. P. & Gorvel, J.-P. (2013). Curr. Opin. Microbiol. 16, 45–51. CrossRef CAS PubMed Google Scholar
Laine, C. G., Johnson, V. E., Scott, H. M. & Arenas-Gamboa, A. M. (2023). Emerg. Infect. Dis. 29, 1789–1797. Web of Science CrossRef PubMed Google Scholar
Lawson, D. M., Artymiuk, P. J., Yewdall, S. J., Smith, J. M. A., Livingstone, J. C., Treffry, A., Luzzago, A., Levi, S., Arosio, P., Cesareni, G., Thomas, C. D., Shaw, W. V. & Harrison, P. M. (1991). Nature, 349, 541–544. CrossRef PubMed CAS Web of Science Google Scholar
Le Vay, K., Carter, B. M., Watkins, D. W., Tang, T.-Y. D., Ting, V. P., Cölfen, H., Rambo, R. P., Smith, A. J., Anderson, J. L. R. & Perriman, A. W. (2020). J. Am. Chem. Soc. 142, 20640–20650. CrossRef CAS PubMed Google Scholar
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J., Richardson, J. S., Richardson, D. C., Sammito, M. D., Sobolev, O. V., Stockwell, D. H., Terwilliger, T. C., Urzhumtsev, A. G., Videau, L. L., Williams, C. J. & Adams, P. D. (2019). Acta Cryst. D75, 861–877. Web of Science CrossRef IUCr Journals Google Scholar
Liu, L., Harmon, E. K., Craig, J. K., Yao, H., Battaile, K. P., Johnson, D. K., Subramanian, S., Van Voorhis, W. C., Rivera, M. & Lovell, S. (2026). Proteins, 94, 1170–1181. CrossRef CAS PubMed Google Scholar
Liu, Y. & Eisenberg, D. (2002). Protein Sci. 11, 1285–1299. Web of Science CrossRef PubMed CAS Google Scholar
Lokamar, P. N., Kutwah, M. A., Atieli, H., Gumo, S. & Ouma, C. (2020). BMC Vet. Res. 16, 61. Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. Web of Science CrossRef CAS IUCr Journals Google Scholar
Mohanty, A., Parida, A., Raut, R. K. & Behera, R. K. (2022). ACS Bio Med Chem Au, 2, 258–281. CrossRef CAS PubMed Google Scholar
Mohanty, A. K. M., Jena, S. S. & Behera, R. K. (2021). Biomacromolecules, 22, 1389–1398. CrossRef CAS PubMed Google Scholar
Mongan, J., Case, D. A. & McCammon, J. A. (2004). J. Comput. Chem. 25, 2038–2048. Web of Science CrossRef PubMed CAS Google Scholar
Moreno, E. (2014). Front. Microbiol. 5, 213. Web of Science CrossRef PubMed Google Scholar
Moriarty, N. W., Grosse-Kunstleve, R. W. & Adams, P. D. (2009). Acta Cryst. D65, 1074–1080. Web of Science CrossRef CAS IUCr Journals Google Scholar
Oscarsson, M., Beteva, A., Flot, D., Gordon, E., Guijarro, M., Leonard, G., McSweeney, S., Monaco, S., Mueller-Dieckmann, C., Nanao, M., Nurizzo, D., Popov, A., von Stetten, D., Svensson, O., Rey-Bakaikoa, V., Chado, I., Chavas, L., Gadea, L., Gourhant, P., Isabet, T., Legrand, P., Savko, M., Sirigu, S., Shepard, W., Thompson, A., Mueller, U., Nan, J., Eguiraun, M., Bolmsten, F., Nardella, A., Milàn-Otero, A., Thunnissen, M., Hellmig, M., Kastner, A., Schmuckermaier, L., Gerlach, M., Feiler, C., Weiss, M. S., Bowler, M. W., Gobbo, A., Papp, G., Sinoir, J., McCarthy, A., Karpics, I., Nikolova, M., Bourenkov, G., Schneider, T., Andreu, J., Cuní, G., Juanhuix, J., Boer, R., Fogh, R., Keller, P., Flensburg, C., Paciorek, W., Vonrhein, C., Bricogne, G. & de Sanctis, D. (2019). J. Synchrotron Rad. 26, 393–405. Web of Science CrossRef IUCr Journals Google Scholar
Parida, A., Bhattacharyya, G., Mallik, S. & Behera, R. K. (2025). Chem. Sci. 16, 3978–3997. CrossRef CAS PubMed Google Scholar
Pfanzagl, V., Beale, J. H., Michlits, H., Schmidt, D., Gabler, T., Obinger, C., Djinović-Carugo, K. & Hofbauer, S. (2020). J. Biol. Chem. 295, 13488–13501. Web of Science CrossRef CAS PubMed Google Scholar
Précigoux, G., Yariv, J., Gallois, B., Dautant, A., Courseille, C. & Langlois d'Estaintot, B. L. (1994). Acta Cryst. D50, 739–743. CrossRef Web of Science IUCr Journals Google Scholar
Pullin, J., Wilson, M. T., Clémancey, M., Blondin, G., Bradley, J. M., Moore, G. R., Le Brun, N. E., Lučić, M., Worrall, J. A. R. & Svistunenko, D. A. (2021). Angew. Chem. Int. Ed. 60, 8361–8369. CrossRef CAS Google Scholar
Qu, Y., Wang, L., Yin, S., Zhang, B., Jiao, Y., Sun, Y., Middelberg, A. & Bi, J. (2021). J. Phys. Chem. B, 125, 3830–3842. CrossRef CAS PubMed Google Scholar
Rivera, M. (2017). Acc. Chem. Res. 50, 331–340. Web of Science CrossRef CAS PubMed Google Scholar
Rodrigues, M. L., Oliveira, T., Matias, P. M., Martins, I. C., Valente, F. M. A., Pereira, I. A. C. & Archer, M. (2006). Acta Cryst. F62, 565–568. CrossRef IUCr Journals Google Scholar
Salcedo, S. P., Marchesini, M. I., Lelouard, H., Fugier, E., Jolly, G., Balor, S., Muller, A., Lapaque, N., Demaria, O., Alexopoulou, L., Comerci, D. J., Ugalde, R. A., Pierre, P. & Gorvel, J.-P. (2008). PLoS Pathog. 4, e21. Web of Science CrossRef PubMed Google Scholar
Saldan, I., Semenyuk, Y., Marchuk, I. & Reshetnyak, O. (2015). J. Mater. Sci. 50, 2337–2354. CrossRef CAS Google Scholar
Song, N., Zhang, J., Zhai, J., Hong, J., Yuan, C. & Liang, M. (2021). Acc. Chem. Res. 54, 3313–3325. CrossRef CAS PubMed Google Scholar
Stein, D., Jartoux, B., Dror, S., Uebe, R., Koubková-Yu, T. C.-T., Zalk, R., Shahar, A., Zarivach, R. & Frank, G. A. (2026). Proc. Natl Acad. Sci. USA, 123, e2504561123. CrossRef PubMed Google Scholar
Swails, J. M., York, D. M. & Roitberg, A. E. (2014). J. Chem. Theory Comput. 10, 1341–1352. CrossRef CAS PubMed Google Scholar
van der Ven, A. M., Gyamfi, H., Suttisansanee, U., Ahmad, M. S., Su, Z., Taylor, R. M., Poole, A., Chiorean, S., Daub, E., Urquhart, T. & Honek, J. F. (2023). Molecules, 28, 4663. CrossRef PubMed Google Scholar
van Eerde, A., Wolterink-van Loo, S., van der Oost, J. & Dijkstra, B. W. (2006). Acta Cryst. F62, 1061–1066. CrossRef IUCr Journals Google Scholar
Velasco, J., Bengoechea, J. A., Brandenburg, K., Lindner, B., Seydel, U., González, D., Zähringer, U., Moreno, E. & Moriyón, I. (2000). Infect. Immun. 68, 3210–3218. CrossRef PubMed CAS Google Scholar
Wang, Q., Mercogliano, C. P. & Löwe, J. (2011). Structure, 19, 147–154. CrossRef CAS PubMed Google Scholar
Wang, Y., Yao, H., Cheng, Y., Lovell, S., Battaile, K. P., Midaugh, C. R. & Rivera, M. (2015). Biochemistry, 54, 6162–6175. CrossRef CAS PubMed Google Scholar
Wang, Z., Li, C., Ellenburg, M., Soistman, E., Ruble, J., Wright, B., Ho, J. X. & Carter, D. C. (2006). Acta Cryst. D62, 800–806. Web of Science CrossRef CAS IUCr Journals Google Scholar
Weeratunga, S. K., Lovell, S., Yao, H., Battaile, K. P., Fischer, C. J., Gee, C. E. & Rivera, M. (2010). Biochemistry, 49, 1160–1175. CrossRef CAS PubMed Google Scholar
Wong, S. G., Tom-Yew, S. A. L., Lewin, A., Le Brun, N. E., Moore, G. R., Murphy, M. E. P. & Mauk, A. G. (2009). J. Biol. Chem. 284, 18873–18881. CrossRef PubMed CAS Google Scholar
Yao, H., Wang, Y., Lovell, S., Kumar, R., Ruvinsky, A. M., Battaile, K. P., Vakser, I. A. & Rivera, M. (2012). J. Am. Chem. Soc. 134, 13470–13481. CrossRef CAS PubMed Google Scholar
Zhang, Z., Witham, S. & Alexov, E. (2011). Phys. Biol. 8, 035001. CrossRef PubMed Google Scholar
Zhen, Z., Tang, W., Chen, H., Lin, X., Todd, T., Wang, G., Cowger, T., Chen, X. & Xie, J. (2013). ACS Nano, 7, 4830–4837. CrossRef CAS PubMed Google Scholar
Zheng, B., Yamashita, I., Uenuma, M., Iwahori, K., Kobayashi, M. & Uraoka, Y. (2009). Nanotechnology, 21, 045305. CrossRef PubMed Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.

journal menu
access



